\
&
Contact us
This was 3 years ago
Locationhybrid (In-person, with an online viewing option)
The two-day conference “Ending gender-based violence (GBV) in academia” is part of the programme of the Czech Presidency of the Council of the European Union (1 July – 31 December 2022). The conference is organised by the Centre for Gender and Science (Czech Academy of Sciences) and supported by the Ministry of Education, Youth and Sports of the Czech Republic.
The first day of the conference has a focus on agenda-setting and the second day on finding solutions. The objectives of the conference are to:
The conference will bring together representatives of national authorities, Research Funding and Performing Organisations and other relevant stakeholders in the European Research Area and beyond in order to advance the debate on the actions needed to improve the protection of students and staff.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.